Aquipta banner Aquipta banner Aquipta banner

DESIGNED TO
PREVENT MIGRAINE^1

AQUIPTA is a simple once-daily tablet that works fast†
to prevent migraine.1,2

^In 3-month clinical studies, AQUIPTA significantly reduced monthly migraine days.1

†In a clinical study, 87.7% of patients who received AQUIPTA 60 mg did not have a migraine on day 1 after first dose compared to 74.8% on placebo.2

MIGRAINE IS MORE THAN A HEADACHE3

Migraine is a disabling neurological condition that is estimated to affect 1 in 7 globally, making it one of the leading causes of disability worldwide.3

decorative

MIGRAINE CAN INCLUDE SYMPTOMS SUCH AS:

  • nausea
  • vomiting
  • fatigue
  • dizziness
  • brain fog
  • difficulties with speech
  • visual disturbances
  • pain (neck and shoulders)
  • numbness and tingling (face or limbs)
  • skin sensitivity
  • light sensitivity
  • sensitivity to sound

MIGRAINE IN NEW ZEALAND

About 750K people live with migraine in New Zealand.3

New Zealand icon
decorative

HIGHER PREVALANCE IN WOMEN

Migraine affects 3x as many women as men.3

WHAT CAUSES A MIGRAINE ATTACK?1,4,5

While research into the exact mechanism that causes migraine is ongoing, a protein called calcitonin gene-related peptide, or CGRP is known to play a role.

During a migraine attack, CGRP levels increase and bind to CGRP receptors resulting in pain and inflammation.

USEFUL RESOURCES FOR MIGRAINE

The following external organisations provide a wealth of resources and information for those living with migraine.

Migraine Foundation Aotearoa New Zealand

Migraine Foundation Aotearoa New Zealand provides a collective voice for people in New Zealand living with this invisible and disabling condition.

Access at:
https://migrainefoundation.org.nz/

Healthify He Puna Waiora

Here you can find information and resources to help you manage your migraines.

Access at:
https://healthify.nz/health-a-z/m/migraine-topics/

Abbreviations: CGRP, calcitonin gene-related peptide.

References: 1. AQUIPTA® (atogepant) Data Sheet. 2. Schwedt TJ, et al. Cephalalgia. 2022;42(1):3-11. 3. Migraine Foundation Aotearoa New Zealand. Migraine in NZ. Available at: https://migrainefoundation.org.nz/about-migraine/migraine-basics/. Accessed June 2024. 4. Russo AF. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 5. Edvinsson L, et al. Nat Rev Neurol. 2018;14(6):338-350.

NZ-AQP-240020. TAPS BG4309. ABB2630. Date prepared September 2024